AMRN Amarin Corp

RNS Number:7652J
Amarin Corporation Plc
12 December 2007


                             AMARIN CORPORATION PLC

LONDON, United Kingdom, December 12, 2007, Amarin Corporation plc ("Amarin" or
the "Company") announces that it is sending to its shareholders today a Notice
of General Meeting and Proxy Form in relation to a General Meeting to be held at
7 Curzon Street, Mayfair, London W1J 5HG at 11 a.m. on 17 January 2008 regarding
the consolidation of every ten Ordinary Shares of �0.05 each in the capital of
the Company into one Ordinary Share of �0.50 each. A copy of each of the Notice
and Proxy Form is available on the Company's website at

http://www.amarincorp.com/investor_relations/egm_2008.472.html

About Amarin

Amarin is committed to improving the lives of patients suffering from central
nervous system and cardiovascular diseases. Our goal is to be a leader in the
research, development and commercialization of novel drugs that address unmet
patient needs.

Amarin's CNS development pipeline includes the recently acquired myasthenia
gravis phase II clinical program and preclinical programs in neuromuscular,
neuronal degenerative and inflammatory diseases; Miraxion for Huntington's
disease; two programs in Parkinson's disease; one in epilepsy; and one in memory
and cognition. Amarin is initiating a series of cardiovascular preclinical and
clinical programs to capitalize on the known therapeutic benefits of essential
fatty acids in cardiovascular disease. Amarin also has a proprietary lipid-based
technology platform for the targeted transport of molecules through the liver
and/or to the brain that can be leveraged in a wide range of disease
applications for its own product pipeline or with potential partners.

Amarin has its primary stock market listing in the U.S. on the NASDAQ Capital
Market ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN")
and IEX ("H2E"), respectively.

Contacts:
Amarin +44 (0) 207 907 2442
Rick Stewart Chief Executive Officer
Alan Cooke President and Chief Financial Officer
investor.relations@amarincorp.com


Investors:
Lippert/Heilshorn & Associates, Inc.
Anne Marie Fields +1 212 838 3777
Bruce Voss +1 310 691 7100

Media:
Powerscourt +44 (0) 207 250 1446
Rory Godson
Sarah Daly


Davy: +353 (0)1 679 6363
Ivan Murphy
Fergal Meegan


Ends.



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
NOEUUOSRBKRUAAA

Amarin (LSE:AMRN)
Historical Stock Chart
From Jun 2024 to Jul 2024

Amarin (LSE:AMRN)
Historical Stock Chart
From Jul 2023 to Jul 2024